The main purpose of this study is to begin to collect information and try to learn whether or
not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating
patients mediastinal large B-cell lymphoma. Recent research has shown that this type of
lymphoma shares features with Hodgkin's lymphoma, including the importance of a particular
pathway in the tumor cells called the NF-kB pathway. VELCADE works in part by blocking this
pathway.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Brigham and Women's Hospital Millennium Pharmaceuticals, Inc.